keyword
MENU ▼
Read by QxMD icon Read
search

toprol

keyword
https://www.readbyqxmd.com/read/22977937/my-mother-was-put-on-the-betablocker-metoprolol-toprol-for-high-blood-pressure-now-she-thinks-her-diabetes-is-out-of-control-because-of-it-can-this-be-possible
#1
(no author information available yet)
No abstract text is available yet for this article.
April 2011: Heart Advisor
https://www.readbyqxmd.com/read/22818065/a-randomized-controlled-phase-iib-trial-of-beta-1-receptor-blockade-for-chronic-degenerative-mitral-regurgitation
#2
RANDOMIZED CONTROLLED TRIAL
Mustafa I Ahmed, Inmaculada Aban, Steven G Lloyd, Himanshu Gupta, George Howard, Seidu Inusah, Kalyani Peri, Jessica Robinson, Patty Smith, David C McGiffin, Chun G Schiros, Thomas Denney, Louis J Dell'Italia
OBJECTIVES: The purpose of the study was to evaluate the effect of long-term β(1)-aderergic receptor (AR) blockade on left ventricular (LV) remodeling and function in patients with chronic, isolated, degenerative mitral regurgitation (MR). BACKGROUND: Isolated MR currently has no proven therapy that attenuates LV remodeling or preserves systolic function. METHODS: Thirty-eight asymptomatic subjects with moderate to severe, isolated MR were randomized either to placebo or β(1)-AR blockade (Toprol-XL, AstraZeneca, London, United Kingdom) for 2 years...
August 28, 2012: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/17576868/metoprolol-reverses-left-ventricular-remodeling-in-patients-with-asymptomatic-systolic-dysfunction-the-reversal-of-ventricular-remodeling-with-toprol-xl-revert-trial
#3
RANDOMIZED CONTROLLED TRIAL
Wilson S Colucci, Theodore J Kolias, Kirkwood F Adams, William F Armstrong, Jalal K Ghali, Stephen S Gottlieb, Barry Greenberg, Michael I Klibaner, Marrick L Kukin, Jennifer E Sugg
BACKGROUND: There are no randomized, controlled trial data to support the benefit of beta-blockers in patients with asymptomatic left ventricular systolic dysfunction. We investigated whether beta-blocker therapy ameliorates left ventricular remodeling in asymptomatic patients with left ventricular systolic dysfunction. METHOD AND RESULTS: Patients with left ventricular ejection fraction <40%, mild left ventricular dilation, and no symptoms of heart failure (New York Heart Association class I) were randomly assigned to receive extended-release metoprolol succinate (Toprol-XL, AstraZeneca) 200 mg or 50 mg or placebo for 12 months...
July 3, 2007: Circulation
https://www.readbyqxmd.com/read/17236889/efficacy-and-safety-of-extended-release-metoprolol-succinate-in-hypertensive-children-6-to-16-years-of-age-a-clinical-trial-experience
#4
RANDOMIZED CONTROLLED TRIAL
Donald L Batisky, Jonathan M Sorof, Jennifer Sugg, Michaelene Llewellyn, Michael Klibaner, James W Hainer, Ronald J Portman, Bonita Falkner et al.
OBJECTIVE: To evaluate the efficacy, tolerability, and blood pressure (BP) lowering effect of extended release metoprolol succinate (ER metoprolol) in children 6 to 16 years of age with established hypertension. STUDY DESIGN: Patients were randomized to one of four treatment arms: placebo or ER metoprolol (0.2 mg/kg, 1.0 mg/kg, or 2.0 mg/kg). Data were analyzed on 140 intent-to-treat patients. RESULTS: Mean age (+/-SD) was 12.5 +/- 2.8 years and mean baseline BP was 132/78 +/- 9/9 mmHg...
February 2007: Journal of Pediatrics
https://www.readbyqxmd.com/read/16682315/the-effects-of-combined-versus-selective-adrenergic-blockade-on-left-ventricular-and-systemic-hemodynamics-myocardial-substrate-preference-and-regional-perfusion-in-conscious-dogs-with-dilated-cardiomyopathy
#5
COMPARATIVE STUDY
Lazaros A Nikolaidis, Indu Poornima, Pratik Parikh, Megan Magovern, You-Tang Shen, Richard P Shannon
OBJECTIVES: Given that adverse effects of chronic sympathetic activation are mediated by all three adrenergic receptor subtypes (beta1, beta2, alpha1), we examined the effects of standard doses of carvedilol and metoprolol succinate (metoprolol controlled release/extended release [CR/XL]) on hemodynamics, myocardial metabolism, and regional organ perfusion. BACKGROUND: Both beta1 selective and combined adrenergic blockade reduce morbidity and mortality in heart failure...
May 2, 2006: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/11714419/debate-do-all-patients-with-heart-failure-require-automatic-implantable-defibrillators-for-the-prevention-of-sudden-death
#6
Sidney Goldstein
Recent clinical trials indicate that approximately two-thirds of patients in New York Heart Association (NYHA) class II and III, who comprise almost 90% of patients with heart failure, die suddenly. Patients in NYHA class IV usually die of progressive heart failure. Implantation of implantable cardioverters defibrillators (ICDs) in this population would represent a huge logistic problem and economic expense. Clinical trials have recently demonstrated that beta-blocker therapy with carvedilol, bisoprolol, and toprol XL decrease the sudden death rate by almost 50%, in addition to impacting significantly on death due to worsening heart failure...
2000: Current Controlled Trials in Cardiovascular Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"